SPC2996 in Chronic Lymphocytic Leukaemia

Santaris Pharma A/S46 enrolled

Overview

The purpose of this study is to determine whether SPC2996 is effective and safe in the treatment of Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL) is the most common leukaemia in adults in the US and most of Western Europe. Many patients suffering from CLL have tumour cells expressing high amounts of Bcl-2 protein. Since over expression of Bcl-2 inhibits apoptosis, it is possible that this gene participates in the pathogenesis of CLL. By lowering the Bcl-2 protein in these tumour cells the cells may go into apoptosis due to changed balance in pro- and anti apoptotic proteins and thereby it might be possible to induce a tumour response. The study is an open-labelled, international, multicenter, dose escalating phase I/II study where patients receive 6, 3, 2 or 1 dose(s) of SPC2996, a LNA antisense molecule against Bcl-2, over a period of up to 2 weeks, and are followed for 6 months.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Chronic Lymphocytic Leukemia

Interventions

SPC2996DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients with relapsed or refractory Chronic Lymphocytic Leukaemia requiring therapy * screening blood sample must show circulating lymphocyte count of more then 5 x 109/L and circulating lymphocytes expressing the phenotype CD5+CD20+CD23+. * The PCR Bcl-2 m-RNA level must be positive * the patients must be 18 years or older and have given informed consent. Exclusion Criteria: * previous treatment with rituximab, alemtuzumab or autologous stem cell transplantation within 6 months prior to Visit 1 or allogeneic stem cell transplantation at any time * patients that received anti-cancer therapy, glucocorticoids or radiotherapy within 4 weeks prior to Visit 1 and patients with known or suspected transformation of CLL

Locations (12)

Holden Comprehensive Cancer Center, Univ. of Iowa

Iowa City, Iowa, United States

Rigshospitalet

Copenhagen, Denmark

KAS Herlev

Herlev, Denmark

Outcomes

Primary Outcomes

Change in Bcl-2 m-RNA levels

Time frame: from Day 0 to Day 13

Secondary Outcomes

Change in Bcl-2 protein expression. Change in Bcl-2 m-RNA levels (and other parameters)

Time frame: from Day 0 to Day 14 and during study respectively

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.